OOIR: Observatory of International Research

Papers

(The TQCC of Current Hematologic Malignancy Reports is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	38
IDH Inhibitors in AML—Promise and Pitfalls	38
MRD Assessment in Multiple Myeloma: Progress and Challenges	34
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments	31
Enteropathy-Associated T cell Lymphoma	20
Treatment-Free Remission: the New Goal in CML Therapy	19
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	18
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	17
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	16
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms	15
Molecular Pathogenesis of Myeloproliferative Neoplasms	15
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding	14
Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges	14
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	14
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	12
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches	12
Future Directions in Chronic Phase CML Treatment	12
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options	11
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms	11
Antibody-Based Treatment Approaches in Multiple Myeloma	11
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	10
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	9
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit	9
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	9
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?	9

An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia	9
The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond	8
BTK Inhibitors in Chronic Lymphocytic Leukemia	8
MRD in ALL: Optimization and Innovations	8
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?	8
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job	8
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management	8
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses	7
Management of Chronic Myeloid Leukemia in Children and Young Adults	7
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra	7
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities	7
Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy	7
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis	7
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	7